Universe Pharmaceuticals Inc
2 hedge funds and large institutions have $40K invested in Universe Pharmaceuticals Inc in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0.03% more ownership
Funds ownership: 0.3% → 0.33% (+0.03%)
33% less funds holding
Funds holding: 3 → 2 (-1)
57% less capital invested
Capital invested by funds: $93.7K → $40K (-$53.7K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$8.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$6.67K |
UPC Hedge Fund Activity: Q1 2023 in Review
2 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in Universe Pharmaceuticals Inc (UPC) for Q1 2023, worth a combined $40K — down 57% from $93.7K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of UPC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $8.62K. The largest seller was UBS Group, exiting entirely with an estimated $6.67K sold.
- 2 institutional investors held Universe Pharmaceuticals Inc (UPC) as of Q1 2023, down from 3 in Q4 2022.
- Funds reported $40K of Universe Pharmaceuticals Inc stock for Q1 2023, down 57% quarter-over-quarter.
- 0 funds opened new Universe Pharmaceuticals Inc positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest Universe Pharmaceuticals Inc buyer in Q1 2023 was Renaissance Technologies, an estimated $8.62K added.
- The largest Universe Pharmaceuticals Inc seller in Q1 2023 was UBS Group, an estimated $6.67K sold.
Based on aggregated 13F filings for Q1 2023.